Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs PanBlok (Primary) ; AS03A; MF 59
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- 23 Feb 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 23 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.